Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

PURPOSE: Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC) who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant tumors. We investigated the efficacy of erlotinib alone or in combination with chemotherapy in patients with these characte...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Jänne, Pasi A., Wang, Xiaofei, Socinski, Mark A., Crawford, Jeffrey, Stinchcombe, Thomas E., Gu, Lin, Capelletti, Marzia, Edelman, Martin J., Villalona-Calero, Miguel A., Kratzke, Robert, Vokes, Everett E., Miller, Vincent A.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2012
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397694/
https://ncbi.nlm.nih.gov/pubmed/22547605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.1315
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items